Abstract: Disclosed is a class of triaromatic compounds targeting a bifunctional phosphorylation site of STAT3, such as compounds represented by formulas (I) to (V), or pharmaceutically acceptable salts, hydrates, solvates, metabolites or prodrugs thereof. Further proposed are pharmaceutical compositions comprising the compounds represented by formulas (I) to (V). Further proposed are applications of the triaromatic compounds in the preparation of drugs for preventing and/or treating diseases caused or regulated by activation of the bifunctional phosphorylation site of STAT3.

Abstract: A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.

Abstract: A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.

Abstract: The present invention relates to methods and compositions for the treatment of angiogenesis and macular degeneration. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of angiogenesis by administering compounds disclosed herein. In further embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In still further embodiments, the invention relates to methods and compositions comprising gambogic acid and gambogic acid derivatives.